Wednesday, July 8, 2026

pharma · Acne Vulgaris · Pruritus · VYNE

VYNE Therapeutics

Vyne Therapeutics (Israel) is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker VYNE. Primary therapeutic focus areas include Acne Vulgaris, Pruritus, Rosacea, Epidermolysis Bullosa,

520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US HQ
2003 Founded
47 Employees
Public company Type
VYNE · NYSE Ticker
Company details
Status
Public
HQ
520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807, US
Founded
2003
Employees
47
Programs
30
Drugs
16
Patents
7
Clinical program

FMX-101

Phase 1 · small molecule · Healthy

FMX-101 for Healthy is a Phase 1 program (small_molecule) at VYNE Therapeutics with 3 ClinicalTrials.gov record(s).

← All VYNE Therapeutics projects Phase 1 small molecule completed

Internal code FX2016-09

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
VYNE Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
completed
Trials
3